Foresite Capital Management II’s Twist Bioscience TWST Stock Holding History

Foresite Capital Management II’s Portfolio TWST Stock Details TWST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-72,849	Closed	-$2.11M	–	8
2019 Q2	$2.11M	Hold	72,849	–	–	1.19%	7
2019 Q1	$1.69M	Hold	72,849	–	–	0.76%	8
2018 Q4	$1.68M	Buy	+72,849	New	+$1.61M	0.89%	9

Other funds holding TWST

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Foresite Capital Management II's TWST Position: Q3 2019 in Review

Foresite Capital Management II sold out of Twist Bioscience (TWST) in Q3 2019, closing a stake of 72,849 shares — an estimated $2.11M sold.

Foresite Capital Management II first reported a position in TWST in Q4 2018 and held it in 3 quarters. The position peaked at $2.11M in Q2 2019. 84 funds tracked by Wall St. Rank hold TWST as of Q3 2019.

Foresite Capital Management II reported no remaining Twist Bioscience position as of Q3 2019 after selling out during the quarter.
Foresite Capital Management II sold 72,849 Twist Bioscience shares in Q3 2019, an estimated $2.11M.
Foresite Capital Management II first reported a position in Twist Bioscience in Q4 2018 and held it in 3 quarters.
Foresite Capital Management II's Twist Bioscience position peaked at $2.11M in Q2 2019.
84 funds tracked by Wall St. Rank held Twist Bioscience as of Q3 2019.

Based on Foresite Capital Management II's 13F filing for Q3 2019, filed 13 Nov 2019.